Abstract
The design, synthesis and evaluation of several dual PPARα/γ agonists with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, quinazolin-4-one and benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes and associated dyslipidemia are described. Among them, compound 5cb was found to possess a potent dual PPARα/β agonist property. It significantly reversed diabetic hyperglycemia while improving overall lipid homeostasis in preclinical animal models.
Keywords: PPAR, Diabetes, Synthesis, Ethyl 3-(4-aminophenyl)-2-ethoxypropionate, Dyslipidemia and Plasma glucose
Letters in Drug Design & Discovery
Title: Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor α/βDual Agonists for the Treatment of Type 2 Diabetes
Volume: 4 Issue: 1
Author(s): Saibal Kumar Das, Chandrasekhar Abbineni, Krovvidi Venkata Lakshmi Narasimha Rao, Javed Iqbal, Ravi Krishna Babu and Ranjan Chakrabarti
Affiliation:
Keywords: PPAR, Diabetes, Synthesis, Ethyl 3-(4-aminophenyl)-2-ethoxypropionate, Dyslipidemia and Plasma glucose
Abstract: The design, synthesis and evaluation of several dual PPARα/γ agonists with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, quinazolin-4-one and benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes and associated dyslipidemia are described. Among them, compound 5cb was found to possess a potent dual PPARα/β agonist property. It significantly reversed diabetic hyperglycemia while improving overall lipid homeostasis in preclinical animal models.
Export Options
About this article
Cite this article as:
Kumar Das Saibal, Abbineni Chandrasekhar, Venkata Lakshmi Narasimha Rao Krovvidi, Iqbal Javed, Krishna Babu Ravi and Chakrabarti Ranjan, Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor α/βDual Agonists for the Treatment of Type 2 Diabetes, Letters in Drug Design & Discovery 2007; 4 (1) . https://dx.doi.org/10.2174/157018007778992883
DOI https://dx.doi.org/10.2174/157018007778992883 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gynecomastia in Infants, Children, and Adolescents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Regenerative Potential of Stem Cells Derived from Human Exfoliated Deciduous (SHED) Teeth during Engineering of Human Body Tissues
Current Stem Cell Research & Therapy Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Current Cancer Drug Targets Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Viral Origins of Human Cancer
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Advances in Quantitative Mass Spectrometry Analysis: Weighing in on Isotope Coding and Label-Free Approaches for Expression and Functional Proteomics
Current Analytical Chemistry Targeted Therapies and other Agents as First-Line Maintenance and Beyond: Particular Benefit in Pulmonary Adenocarcinoma Patients
Current Medicinal Chemistry Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) The Methylerythritol Phosphate Pathway and its Significance as a Novel Drug Target
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: “miRNA and Cancer; Computational and Experimental Approaches”)
Current Pharmaceutical Biotechnology Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery